U.S. Food and Drug Administration approves a new drug designed to help those with constipation and irritable bowel syndrome
August 31, 2012- The U.S. Food and Drug Administration approved on Thursday a new drug designed to help those with constipation and irritable bowel syndrome. Forest Laboratories and Ironwood Pharmaceuticals Inc. develop the new drug.
Linzess was approved by the regulatory agency as an irritable bow syndrome treatment as well as for chronic constipation that other treatments are not able to help. Over 10 million people in the U.S. alone are believed to suffer from the two conditions. A market analyst said the sales annually for the new drug could pass $2 billion. During the fourth quarter of this year, the companies expect to launch the new medication.
The medication has been considered a major drug for both Forest and Ironwood. It comes in capsule form and is intended to be ingested once each day when the stomach is empty, 30 minutes prior to the first meal eaten in the day. It is approved for adults and will contain a warning on the label that says it should not be used for people younger than 16.
Analysts said that even though the drug is less profitable compared to other drugs the two companies sell, this could be one of the biggest and most important products the companies manufacture. The cost for the medication to the public will be approximately $7 per day.